Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials.

Hdl Handle:
http://hdl.handle.net/10147/596595
Title:
Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials.
Authors:
Singh, Mohit; Keer, Dipinder; Klimas, Jan; Wood, Evan; Werb, Dan
Citation:
Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. 2016: Addiction
Journal:
Addiction (Abingdon, England)
Issue Date:
30-Jan-2016
URI:
http://hdl.handle.net/10147/596595
DOI:
10.1111/add.13328
PubMed ID:
26826006
Abstract:
To assess the efficacy of topiramate in treating cocaine use disorder (i.e., retention, efficacy, safety, and craving reduction) through a systematic review and meta-analysis.; We searched six scientific databases from inception to December 23, 2014 with no date limits. Data were systematically reviewed, extracted and analyzed. Studies were included if they were peer-reviewed randomized control trials with participants meeting diagnostic criteria for cocaine dependence or cocaine use disorder, with the treatment arm involving topiramate with or without psychosocial intervention, and the control arm involving no intervention or psychosocial intervention with or without placebo. A random-effects meta-analytic model was computed.; Five studies met inclusion criteria (n = 518). Topiramate was compared with placebo (4 studies), and no medication (1 study). In a meta-analysis, we observed no significant differences between topiramate and placebo in improving treatment retention (risk ratio [RR] = 0.84; 95% Confidence Interval [CI]: 0.67-1.05, p = 0.12). However, compared with a placebo, use of topiramate was associated with increased continuous abstinence in two of five studies (RR = 2.52; 95% CI: 1.35-4.73, p = 0.004). No differences were observed in frequency of adverse effects reported between topiramate and placebo (RR=1.03; 95% CI = 0.87-1.23, p=0.72). Topiramate was significantly associated (p<0.05) with a reduction in craving in only one of five studies.; Evidence does not currently support the use of topiramate to improve treatment retention for cocaine use disorder, though it may extend cocaine abstinence with a similar risk of adverse events compared with placebo.
Item Type:
Article In Press
Language:
en
Keywords:
COCAINE-RELATED DISORDERS; SUBSTANCE MISUSE; ADDICTION
ISSN:
1360-0443

Full metadata record

DC FieldValue Language
dc.contributor.authorSingh, Mohiten
dc.contributor.authorKeer, Dipinderen
dc.contributor.authorKlimas, Janen
dc.contributor.authorWood, Evanen
dc.contributor.authorWerb, Danen
dc.date.accessioned2016-02-18T10:01:05Zen
dc.date.available2016-02-18T10:01:05Zen
dc.date.issued2016-01-30en
dc.identifier.citationTopiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. 2016: Addictionen
dc.identifier.issn1360-0443en
dc.identifier.pmid26826006en
dc.identifier.doi10.1111/add.13328en
dc.identifier.urihttp://hdl.handle.net/10147/596595en
dc.description.abstractTo assess the efficacy of topiramate in treating cocaine use disorder (i.e., retention, efficacy, safety, and craving reduction) through a systematic review and meta-analysis.en
dc.description.abstractWe searched six scientific databases from inception to December 23, 2014 with no date limits. Data were systematically reviewed, extracted and analyzed. Studies were included if they were peer-reviewed randomized control trials with participants meeting diagnostic criteria for cocaine dependence or cocaine use disorder, with the treatment arm involving topiramate with or without psychosocial intervention, and the control arm involving no intervention or psychosocial intervention with or without placebo. A random-effects meta-analytic model was computed.en
dc.description.abstractFive studies met inclusion criteria (n = 518). Topiramate was compared with placebo (4 studies), and no medication (1 study). In a meta-analysis, we observed no significant differences between topiramate and placebo in improving treatment retention (risk ratio [RR] = 0.84; 95% Confidence Interval [CI]: 0.67-1.05, p = 0.12). However, compared with a placebo, use of topiramate was associated with increased continuous abstinence in two of five studies (RR = 2.52; 95% CI: 1.35-4.73, p = 0.004). No differences were observed in frequency of adverse effects reported between topiramate and placebo (RR=1.03; 95% CI = 0.87-1.23, p=0.72). Topiramate was significantly associated (p<0.05) with a reduction in craving in only one of five studies.en
dc.description.abstractEvidence does not currently support the use of topiramate to improve treatment retention for cocaine use disorder, though it may extend cocaine abstinence with a similar risk of adverse events compared with placebo.en
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Addiction (Abingdon, England)en
dc.subjectCOCAINE-RELATED DISORDERSen
dc.subjectSUBSTANCE MISUSEen
dc.subjectADDICTIONen
dc.titleTopiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials.en
dc.typeArticle In Pressen
dc.identifier.journalAddiction (Abingdon, England)en

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.